The phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of
rapamycin (mTOR) pathway is a well studied signaling pathway that regulates diverse …

Background Cisplatin-based regimens are routinely employed for the treatment of urothelial
carcinoma. However, therapeutic success is hampered by the primary presence of or the …

Background Lumbrokinase (LK) is an enzyme complex with antithrombotic, antioxidant,
antitumor, and immunomodulatory effects. It has been extensively studied and used in …

Previous in vitro and case–control studies have found an association between the insulin‐
like growth factor (IGF)‐axis and bladder cancer risk. Circulating concentrations of IGF‐I …

Clinical outcomes for patients with bladder cancer have largely remained unchanged over
the last three decades despite improvements in surgical techniques, perioperative therapies …

Non-muscle-invasive bladder cancer accounts for the majority of incident bladder cancers
but is a heterogeneous disease with variation in clinical presentation, course, and outcomes …

Bladder cancer remains a global epidemiologic problem, with a strong male predominance
and association with tobacco smoking. However, several other risk factors have also been …

One of the questions that have recently emerged is whether, in the era of whole-genome
analyses of human specimens, modeling bladder cancer in mice is still necessary. To …

Die zielgerichtete Inhibierung des PI3K/AKT/mTOR-Signalwegs ist ein neuer
Therapieansatz in der Behandlung des Harnblasenkarzinoms. Wir charakterisierten die …

Introduction: Bladder cancer (BC) is highly prevalent. It presents as either non-muscle
invasive or muscle-invasive disease. The prognosis of muscle invasive disease is poor, with …